GO:0015179 L-amino acid transmembrane transporter activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0015179 describes the molecular function of moving L-enantiomer amino acids across biological membranes, a process essential for nutrient uptake, inter-organ nitrogen flux, and neurotransmitter precursor supply.
• The y+L amino acid transporter is a heteromultimeric complex in which a light chain (SLC7A7) associates with the heavy chain 4F2hc (SLC3A2) to catalyze L-amino acid transport.
• Mutations in SLC7A7, the gene encoding the y+LAT-1 light chain, are the molecular cause of lysinuric protein intolerance, a rare inherited disorder of dibasic amino acid transport.
• The LAT family member SteT uses transmembrane domain 8 as a structural determinant of substrate selectivity and translocation, illustrating how single domains tune transport specificity.
• SLC1A5 (ASCT2) is a glutamine transporter whose expression is regulated by the lncRNA SLC1A5-AS/MZF1 axis and contributes to malignant progression of hepatocellular carcinoma.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of transporter function in cells and animal models.
Description
L-amino acid transmembrane transporter activity (GO:0015179) is a molecular function that enables the transfer of L-enantiomer amino acids from one side of a membrane to the other. This activity is fundamental to cellular nutrition, because most cells cannot synthesize all twenty proteinogenic amino acids and must import them from the extracellular environment or from the circulation. Transporters carrying this activity also supply precursors for neurotransmitters, nucleotides, and glutathione, and they participate in inter-organ nitrogen shuttling between muscle, liver, and kidney. The functional unit responsible for this activity is often a heteromultimeric complex. The y+L amino acid transporter, for example, consists of a catalytic light chain (y+LAT-1, encoded by SLC7A7) covalently linked to the type II membrane glycoprotein 4F2hc (SLC3A2). The heavy chain is required for surface expression and stability, whereas the light chain determines substrate selectivity and transport kinetics. This architecture is shared by several L-amino acid transporter (LAT) family members, making GO:0015179 a paradigm for studying how membrane proteins are assembled and regulated. For researchers, GO:0015179 matters because defects in L-amino acid transport underlie human disease, including lysinuric protein intolerance and metabolic reprogramming in cancer. Understanding which genes carry this activity, how they are regulated, and how they can be modeled with CRISPR is therefore central to both basic membrane biology and translational research.
L-amino acid transmembrane transporter activity At A Glance
| GO ID | GO:0015179 |
|---|---|
| GO term | L-amino acid transmembrane transporter activity |
| Ontology | molecular_function |
| Synonym | L-amino acid transporter activity |
| Definition | Enables the transfer of an L-amino acid from one side of a membrane to the other; L-amino acids are the L-enantiomers of amino acids. |
| Major function | Mediates uptake or efflux of L-amino acids across cellular membranes, supporting nutrient supply, nitrogen flux, and neurotransmitter precursor availability. |
| Representative complex | y+L amino acid transporter, a heteromultimer of SLC7A7 (y+LAT-1) and SLC3A2 (4F2hc). |
| Disease relevance | Mutations in SLC7A7 cause lysinuric protein intolerance; altered SLC1A5 expression is linked to hepatocellular carcinoma progression. |
| Research methods | CRISPR knockout, point mutation, knock-in, overexpression, transport assays, and transcriptomic/proteomic profiling. |
What Is GO:0015179?
GO:0015179, L-amino acid transmembrane transporter activity, is defined as the molecular function that enables the transfer of an L-amino acid from one side of a membrane to the other, where L-amino acids are the L-enantiomers of amino acids. In practical terms, a protein annotated with this term binds an L-amino acid and moves it across a lipid bilayer, either down its concentration gradient or coupled to the movement of another solute. The term is a molecular_function annotation and is often used alongside more specific child terms that describe the particular substrate or coupling mechanism, such as system y+L activity.
Why Is L-amino acid transmembrane transporter activity Important in Cell Biology?
GO:0015179 is important because L-amino acid transport sits at the intersection of nutrition, metabolism, and signaling. Cells depend on this activity to acquire essential amino acids, and tissues such as kidney and intestine use it to reabsorb and distribute amino acids throughout the body. When this function is impaired, the consequences can be severe: loss of y+LAT-1 causes lysinuric protein intolerance, a disorder characterized by defective dibasic amino acid transport. In cancer, transporters carrying this activity, such as SLC1A5, can be co-opted to support the metabolic demands of rapidly proliferating cells. Because the activity is mediated by multi-subunit complexes, it also provides a tractable system for studying membrane protein assembly, substrate selectivity, and regulation.
• Provides essential amino acids that cells cannot synthesize, supporting protein synthesis and growth.
• Enables renal and intestinal reabsorption of dibasic amino acids, preventing urinary loss.
• Supplies neurotransmitter precursors such as tryptophan and tyrosine to the brain.
• Supports inter-organ nitrogen shuttling between muscle, liver, and kidney.
• Is a determinant of drug pharmacokinetics when transporters recognize amino acid-like compounds.
• Contributes to cancer metabolic reprogramming, notably glutamine uptake via SLC1A5.
• Serves as a model for heteromultimeric membrane protein assembly and trafficking.
• Offers a target for treating inherited transport disorders such as lysinuric protein intolerance.
• Can be studied with CRISPR models to establish causal gene-disease links.
• Informs the design of peptide-based therapeutics that mimic or inhibit amino acid transport.
What Happens During L-amino acid transmembrane transporter activity?
Substrate recognition and binding
In simple terms: The transporter first grabs the amino acid it is designed to carry.
The transport cycle begins when the light chain of the transporter, such as y+LAT-1, binds an L-amino acid from the extracellular or intracellular side of the membrane. Substrate recognition depends on specific residues within the transmembrane domains; in the LAT family member SteT, transmembrane domain 8 contributes to substrate selectivity and translocation. This step determines which amino acids can be transported and is therefore a key target for mutagenesis studies.
Conformational change and translocation
In simple terms: The transporter changes shape to move the amino acid across the membrane.
After binding, the transporter undergoes a conformational change that exposes the substrate to the opposite side of the membrane. For the y+L system, this translocation is coupled to the movement of another solute, and the heteromultimeric complex with 4F2hc is required for efficient transport. The heavy chain 4F2hc does not itself carry the substrate but is essential for the light chain to reach the cell surface and function.
Substrate release and resetting
In simple terms: The amino acid is released inside the cell and the transporter resets for another round.
Once the substrate reaches the target compartment, it is released and the transporter returns to its initial conformation. This resetting step allows repeated cycles of transport and is influenced by the electrochemical gradient and the availability of coupling ions. Mutations that impair resetting can reduce transport capacity even when substrate binding is preserved.
Assembly of the heteromultimeric complex
In simple terms: Two different protein chains must come together for the transporter to work.
The y+L amino acid transporter is a heteromultimeric complex composed of a catalytic light chain and the heavy chain 4F2hc. The heavy chain is a type II membrane glycoprotein that associates with the light chain through a disulfide bond and is required for surface expression. This assembly step is a prerequisite for GO:0015179 activity in the y+L system and illustrates how molecular function can depend on multiple gene products.
Regulation by cellular demand
In simple terms: The cell adjusts how much transport it does based on its needs.
Transport activity is tuned to cellular demand, and expression of transporter genes can be regulated at the transcriptional level. For example, the lncRNA SLC1A5-AS/MZF1 axis regulates SLC1A5 expression and thereby influences glutamine transport in hepatocellular carcinoma cells. Such regulation links GO:0015179 activity to growth, proliferation, and metabolic stress responses.
Key Genes Involved in GO:0015179 L-amino acid transmembrane transporter activity
The following genes encode proteins that carry or regulate L-amino acid transmembrane transporter activity, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLC7A7 | Light chain of the y+L amino acid transporter (y+LAT-1); catalytic subunit for L-amino acid transport | Mutations cause lysinuric protein intolerance; model for dibasic amino acid transport |
| SLC3A2 | Heavy chain 4F2hc; required for surface expression and function of y+LAT-1 | Essential partner for heteromultimeric transporter assembly |
| SLC1A5 | Glutamine transporter (ASCT2); supports amino acid uptake in cancer cells | Regulated by lncRNA SLC1A5-AS/MZF1; linked to hepatocellular carcinoma progression |
| SLC7A6 | Related light chain that can associate with 4F2hc to form y+L-like transport activity | Used to study heteromultimer specificity and substrate selectivity |
| SLC7A5 | LAT1 light chain that partners with 4F2hc for large neutral amino acid transport | Model for understanding LAT family assembly and function |
| SLC7A8 | LAT2 light chain that partners with 4F2hc | Comparative studies of L-amino acid transporter isoforms |
| SteT | Bacterial LAT family member used as a structural model | Transmembrane domain 8 studied for substrate selectivity and translocation |
| MZF1 | Transcription factor implicated in SLC1A5 regulation | Potential target for modulating glutamine transport in cancer |
| SLC1A5-AS | Long non-coding RNA antisense to SLC1A5 | Regulatory node in the SLC1A5-AS/MZF1/ASCT2 axis |
| LPHN3 | Latrophilin-3; not a transporter but used in knockout studies of behavior | Illustrates CRISPR knockout methodology applicable to transporter research |
| ATLX-0199 | Agent that increases minute ventilation; its erythrocytic metabolism involves amino acid-related pathways | Example of pharmacological context for amino acid transport |
| Antimicrobial peptides | Amphipathic alpha-helical peptides whose diastereomers affect activity | Model for peptide-membrane interactions relevant to transport studies |
| 4F2hc | Alternative name for SLC3A2 heavy chain | Key component of y+L transport activity |
| y+LAT-1 | Alternative name for SLC7A7 light chain | Catalytic subunit of the y+L transporter |
| ASCT2 | Alternative name for SLC1A5 | Glutamine transporter in cancer metabolism |
| SLC7 family | Family of light chains that partner with 4F2hc | Broad family for comparative transport studies |
How Is L-amino acid transmembrane transporter activity Regulated?
L-amino acid transmembrane transporter activity is regulated at multiple levels. Transcriptional regulation is exemplified by the lncRNA SLC1A5-AS/MZF1 axis, which controls SLC1A5 expression and glutamine transport in hepatocellular carcinoma. At the protein level, the y+L transporter requires assembly with the 4F2hc heavy chain for surface expression and function, so regulation of SLC3A2 abundance or trafficking directly impacts transport activity. Substrate selectivity can also be tuned by structural elements within the transporter, as shown for transmembrane domain 8 of SteT. Together, these layers allow cells to adjust amino acid uptake to match metabolic demand.
L-amino acid transmembrane transporter activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC7A7 | Lysinuric protein intolerance; defective dibasic amino acid transport | Knockout or point-mutation cell and animal models |
| SLC1A5 | Hepatocellular carcinoma progression; glutamine metabolism | Overexpression and knockout in liver cancer cell lines |
| SLC3A2 | Required for y+L transporter function; potential modifier of transport disorders | Knockout and tagged knock-in for trafficking studies |
| MZF1 | Transcriptional regulation of SLC1A5 in cancer | Knockout and overexpression in cancer models |
| LPHN3 | Hyperactivity and dopamine marker disruption in knockout rats | CRISPR knockout rat model |
Lysinuric protein intolerance
Lysinuric protein intolerance is a rare inherited disorder caused by mutations in SLC7A7, which encodes the y+LAT-1 light chain of the y+L amino acid transporter. Loss of functional y+LAT-1 impairs dibasic amino acid transport, leading to the clinical manifestations of the disease. The identification of SLC7A7 as the candidate gene for this disorder established a direct link between GO:0015179 activity and human pathology.
Cancer metabolism
In hepatocellular carcinoma, the lncRNA SLC1A5-AS/MZF1/ASCT2 axis contributes to malignant progression by regulating SLC1A5 expression and glutamine transport. This illustrates how transporters carrying L-amino acid transmembrane transporter activity can be co-opted to support the metabolic demands of cancer cells. Targeting such transporters is therefore an area of active investigation.
Neurological and behavioral phenotypes
Although latrophilin-3 is not itself an L-amino acid transporter, knockout studies in rats have shown that disrupting membrane protein genes can cause hyperactivity and disrupted dopamine markers. Such work provides methodological parallels for studying how transporter dysfunction might affect behavior and neurotransmission.
From L-amino acid transmembrane transporter activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of SLC7A7 reduce L-amino acid transport? | SLC7A7 knockout cell line |
| Which residues determine substrate selectivity? | Point-mutation knock-in of transporter residues |
| How does 4F2hc affect surface expression? | Tagged knock-in of SLC3A2 |
| Does SLC1A5 overexpression drive proliferation? | SLC1A5 overexpression in cancer cells |
| What is the role of MZF1 in SLC1A5 regulation? | MZF1 knockout and overexpression |
| Can transporter dysfunction alter behavior? | CRISPR knockout animal models |
How to Study the L-amino acid transmembrane transporter activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radiolabeled transport assay | Rate of L-amino acid uptake or efflux | Functional validation of transporter genes |
| RNA sequencing | Transcript abundance and regulatory networks | Identifying transporter regulation in cancer |
| Proteomics | Protein expression and interactions | Studying heteromultimeric complex assembly |
| Site-directed mutagenesis | Effect of specific residues on transport | Mapping substrate selectivity determinants |
| CRISPR knockout | Loss-of-function phenotype | Causal gene-disease studies |
| CRISPR knock-in | Effect of precise sequence changes | Modeling patient mutations |
| Overexpression | Gain-of-function phenotype | Testing oncogenic potential of transporters |
| Behavioral assays | Neurological and behavioral outcomes | Studying membrane protein genes in animal models |
Transport assays
Direct measurement of L-amino acid transport is typically performed using radiolabeled or fluorescent substrates in cells expressing the transporter of interest. Such assays can distinguish between different transport systems and are used to validate the function of candidate genes such as SLC7A7 and SLC3A2.
Transcriptomic and proteomic profiling
RNA sequencing and proteomics can reveal changes in transporter expression and identify regulatory networks, such as the SLC1A5-AS/MZF1 axis in hepatocellular carcinoma. These approaches help link GO:0015179 activity to broader cellular programs.
Mutagenesis and structure-function studies
Site-directed mutagenesis of transporter domains, such as transmembrane domain 8 of SteT, allows researchers to map residues that control substrate selectivity and translocation. Combining mutagenesis with transport assays provides mechanistic insight into GO:0015179.
CRISPR-based genetic models
CRISPR knockout, point mutation, knock-in, and overexpression models enable causal testing of transporter gene function in relevant cell types and organisms. These models are particularly valuable for distinguishing correlation from causation in disease studies.
How CRISPR Can Be Used to Study GO:0015179 L-amino acid transmembrane transporter activity
Knockout
CRISPR knockout of transporter genes such as SLC7A7 or SLC1A5 can abolish L-amino acid transmembrane transporter activity and reveal its contribution to cell growth, metabolism, and disease phenotypes. Knockout models are essential for establishing causality and for validating therapeutic targets.
Point Mutation
Point mutations can be introduced to mimic patient variants or to probe structure-function relationships, as demonstrated by studies of transmembrane domain 8 in SteT. Such models help determine whether a specific residue is required for substrate recognition or translocation.
Knock-in
Knock-in of tagged or reporter versions of transporter genes, such as SLC3A2, allows tracking of protein localization, trafficking, and assembly with partner subunits. This approach is valuable for studying the heteromultimeric nature of the y+L transporter.
Overexpression
Overexpression of transporters like SLC1A5 can drive increased amino acid uptake and support malignant phenotypes in cancer models. Overexpression studies complement loss-of-function approaches and help define the oncogenic potential of transporter genes.
How EDITGENE Supports L-amino acid transmembrane transporter activity Research
Researchers studying L-amino acid transmembrane transporter activity-related genes often need to determine whether a candidate gene is causally involved in a specific phenotype, such as altered amino acid uptake, metabolic reprogramming, or disease progression. Establishing causality requires precise genetic models that can knock out, mutate, tag, or overexpress the gene of interest in relevant cell types. EDITGENE provides end-to-end CRISPR services to generate such models and to support downstream functional and bioinformatic analysis.
Contact EDITGENE today to design your custom CRISPR model for L-amino acid transmembrane transporter activity research.
Frequently Asked Questions About L-amino acid transmembrane transporter activity
What is GO:0015179?
GO:0015179 is the Gene Ontology molecular function term for L-amino acid transmembrane transporter activity, which enables the transfer of an L-amino acid from one side of a membrane to the other.
What genes are involved in L-amino acid transmembrane transporter activity?
Key genes include SLC7A7, which encodes the y+LAT-1 light chain, and SLC3A2, which encodes the 4F2hc heavy chain; SLC1A5 encodes the glutamine transporter ASCT2.
What is the y+L amino acid transporter?
The y+L amino acid transporter is a heteromultimeric complex of a catalytic light chain and the 4F2hc heavy chain that mediates L-amino acid transport.
How is L-amino acid transport regulated?
It is regulated at transcriptional and protein levels, including by the lncRNA SLC1A5-AS/MZF1 axis and by assembly with the 4F2hc heavy chain.
What diseases are linked to L-amino acid transporters?
Mutations in SLC7A7 cause lysinuric protein intolerance, and altered SLC1A5 expression is linked to hepatocellular carcinoma progression.
What is lysinuric protein intolerance?
It is a rare inherited disorder caused by mutations in SLC7A7 that impair dibasic amino acid transport.
How can CRISPR be used to study L-amino acid transporters?
CRISPR knockout, point mutation, knock-in, and overexpression can be used to test the causal role of transporter genes in cells and animal models.
What methods measure L-amino acid transport activity?
Radiolabeled or fluorescent transport assays, mutagenesis, RNA sequencing, proteomics, and CRISPR-based models are commonly used.
What is the role of SLC1A5 in cancer?
SLC1A5 encodes a glutamine transporter that supports malignant progression in hepatocellular carcinoma and is regulated by the SLC1A5-AS/MZF1 axis.
Why is transmembrane domain 8 important in LAT family transporters?
Studies of SteT show that transmembrane domain 8 contributes to substrate selectivity and translocation, making it a key structural determinant.
Conclusion
GO:0015179, L-amino acid transmembrane transporter activity, is a fundamental molecular function that supports nutrient uptake, nitrogen flux, and neurotransmitter precursor supply. Its best-characterized example, the y+L amino acid transporter, is a heteromultimeric complex of SLC7A7 and SLC3A2, and mutations in SLC7A7 cause lysinuric protein intolerance. Other transporters such as SLC1A5 contribute to cancer metabolism and are subject to complex regulation. Studying this activity requires a combination of transport assays, mutagenesis, and CRISPR-based genetic models to establish causality. EDITGENE provides the knockout, point-mutation, knock-in, overexpression, library screening, and bioinformatics services needed to dissect the genes and pathways that carry or regulate L-amino acid transmembrane transporter activity.
References
- 1. Torrents D et al.. 1998. Identification and characterization of a membrane protein (y+L amino acid transporter-1) that associates with 4F2hc to encode the amino acid transport activity y+L. A candidate gene for lysinuric protein intolerance.. J Biol Chem 273(49):32437-45 PMID: 9829974
- 2. Estévez R et al.. 1998. The amino acid transport system y+L/4F2hc is a heteromultimeric complex.. FASEB J 12(13):1319-29 PMID: 9761775
- 3. Bartoccioni P et al.. 2010. Role of transmembrane domain 8 in substrate selectivity and translocation of SteT, a member of the L-amino acid transporter (LAT) family.. J Biol Chem 285(37):28764-76 PMID: 20610400
- 4. Yao SY et al.. 1998. Cloning and functional expression of a cDNA from rat jejunal epithelium encoding a protein (4F2hc) with system y+L amino acid transport activity.. Biochem J 330 ( Pt 2)(Pt 2):745-52 PMID: 9480885
- 5. Krasinkiewicz JM et al.. 2023. Erythrocytic metabolism of ATLX-0199: An agent that increases minute ventilation.. Biochem Biophys Res Commun 680:171-176 PMID: 37741264
- 6. Jiang J et al.. 2023. LncRNA SLC1A5-AS/MZF1/ASCT2 Axis Contributes to Malignant Progression of Hepatocellular Carcinoma.. Discov Med 35(179):995-1014 PMID: 38058065
- 7. Papo N et al.. 2002. The consequence of sequence alteration of an amphipathic alpha-helical antimicrobial peptide and its diastereomers.. J Biol Chem 277(37):33913-21 PMID: 12110678
- 8. Regan SL et al.. 2019. Knockout of latrophilin-3 in Sprague-Dawley rats causes hyperactivity, hyper-reactivity, under-response to amphetamine, and disrupted dopamine markers.. Neurobiol Dis 130:104494 PMID: 31176715
